Treating bile duct cancer that has spread to a liver artery
Part of Cancer clinical trials.
This trial tests a treatment plan for people with bile duct cancer that has invaded the main liver artery, making surgery difficult. The treatment is given before surgery to shrink the tumor and improve the chances of successful removal.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with bile duct cancer that has spread into the main artery of the liver.
- You are between 18 and 80 years old.
- You are generally healthy enough for daily activities (ECOG score 0-1).
- Your liver function is not severely impaired (Child-Pugh score of A or B).
- You have not had other cancers in the past 5 years (except cured skin or cervical cancer).
- You are not pregnant or breastfeeding, and you have no severe heart, lung, or kidney disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests delivering two chemotherapy medicines directly into the liver’s artery in people with bile duct cancer inside the liver that cannot be removed with curative surgery. It aims to control the cancer after first-line treatment and see how well this targeted approach works.
This trial is testing a treatment plan that first delivers chemotherapy directly into the liver (through a thin tube) along with standard IV chemotherapy. The goal is to shrink the tumor enough to allow for surgery or less aggressive treatment later. It is for people with bile duct or gallbladder cancer that has not spread far.
This trial combines a liver-directed radiation therapy (radioembolization) with a targeted drug to treat a specific type of bile duct cancer that cannot be surgically removed. The goal is to see if this combination can shrink the tumor and improve outcomes.
This trial tests if adding a combination of immunotherapy (adebrelimab), a targeted drug (apatinib), and chemotherapy into the liver artery (HAIC) before and after surgery can help people with resectable intrahepatic cholangiocarcinoma (a type of bile duct cancer). The goal is to see if this approach improves outcomes.
This trial combines proton beam therapy with a liver transplant to treat a specific type of bile duct cancer (hilar cholangiocarcinoma). It aims to improve outcomes by using radiation before surgery to help make the transplant more successful.
This study tests giving chemo and radiation before a liver transplant for an unresectable bile duct cancer near the liver (hCCA). If your cancer can’t be removed with surgery right now, this approach aims to shrink and control it so transplant may become an option.
Hear when a new Cholangiocarcinoma Non-resectable trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.